243 Efficient generation of CD8+ TSCM CD19 chimeric antigen receptor T-cells (CAR-T cells) by treatment with novel cytokine-based scaffolds

243 Efficient generation of CD8+ TSCM CD19 chimeric antigen receptor T-cells (CAR-T cells) by treatment with novel cytokine-based scaffolds

Bibliographic Details
Main Authors:	Hing C Wong, Harris Goldstein, Moriah Rabin, Erin Cole, Jian Hua Zheng, Niraj Shrestha
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

295 Novel T-cell immunotherapeutics enable the selective generation of more potently cytotoxic CD19 chimeric antigen receptor T-cells (CAR-T cells) from CMV-specific cytotoxic T-cells
by: Scott Garforth, et al.
Published: (2023-11-01)

Efficient derivation of chimeric-antigen receptor-modified TSCM cells
by: Emiko Kranz, et al.
Published: (2022-07-01)

Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
by: Silvia Arcangeli, et al.
Published: (2020-06-01)

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells
by: Blair B. Madison, et al.
Published: (2022-09-01)

Most Do, but Some Do Not: CD4+CD25− T Cells, but Not CD4+CD25+ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
by: Andreas A. Hombach, et al.
Published: (2017-08-01)

Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness.
by: Pedro Costa Del Amo, et al.
Published: (2018-06-01)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
by: Yun Liang, et al.
Published: (2021-02-01)

Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy
by: Louis R. Joslyn, et al.
Published: (2024-01-01)

123 P-MUC1C-ALLO1: A fully allogeneic stem cell memory T cell (TSCM) CAR-T therapy with broad potential in solid tumor
by: Yan Zhang, et al.
Published: (2021-11-01)

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
by: Bipulendu Jena, et al.
Published: (2013-01-01)

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
by: Isabel Martínez-Romera, et al.
Published: (2022-08-01)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
by: Yongxian Hu, et al.
Published: (2016-08-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
by: Ethan A. Burns, et al.
Published: (2021-03-01)

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
by: Na Zheng, et al.
Published: (2024-01-01)

CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype
by: Dong Hoon Lee, et al.
Published: (2023-11-01)

P827: STUDY ON THE PERCENTAGE AND FUNCTION OF TSCM CELLS AND THE ANTITUMOR EFFECT IN VITRO AMPLIFICATION IN PATIENTS WITH MULTIPLE MYELOMA
by: Panpan Cao, et al.
Published: (2023-08-01)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
by: Nathan J. Fergusson, et al.
Published: (2023-04-01)

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
by: Le Qin, et al.
Published: (2022-10-01)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
by: Shouheng Lin, et al.
Published: (2021-04-01)

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
by: Yuan Xia, et al.
Published: (2022-12-01)

TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
by: Kyung-Eun Noh, et al.
Published: (2021-08-01)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
by: Zhenzhen Wang, et al.
Published: (2023-10-01)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
by: Gaia Alberti, et al.
Published: (2023-05-01)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
by: Anett Pfeiffer, et al.
Published: (2018-11-01)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
by: Ivetta Danylesko, et al.
Published: (2023-08-01)

279 Preclinical evaluation of allogeneic CD19 CAR T cells expressing an anti-rejection CD70 CAR
by: Kristen Zhang, et al.
Published: (2023-11-01)

683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)
by: Robert Emmons, et al.
Published: (2023-11-01)

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
by: Eiji Kobayashi, et al.
Published: (2023-08-01)

Chimeric Antigen Receptor beyond CAR-T Cells
by: Vicky Mengfei Qin, et al.
Published: (2021-01-01)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
by: Yao Sun, et al.
Published: (2021-10-01)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
by: Michael A. Morgan, et al.
Published: (2021-07-01)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
by: Julia Hambach, et al.
Published: (2020-01-01)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
by: Michael Green, et al.
Published: (2023-11-01)

Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
by: J Joseph Melenhorst, et al.
Published: (2024-03-01)

Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.
by: Mendes, R, et al.
Published: (2000)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
by: Wenjie Li, et al.
Published: (2023-03-01)

Complications after CD19+ CAR T-Cell Therapy
by: Olaf Penack, et al.
Published: (2020-11-01)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
by: Hanfei Guo, et al.
Published: (2022-03-01)

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
by: Alice Bergamini, et al.
Published: (2023-01-01)